Ignite Creation Date:
2024-05-06 @ 8:23 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06362369
Status:
RECRUITING
Last Update Posted:
2024-05-31
First Post:
2024-03-21
Brief Title:
A Study of Oral 7HP349 Alintegimod in Combination with Ipilimumab Followed by Nivolumab Monotherapy
Sponsor:
7 Hills Pharma LLC
Organization:
7 Hills Pharma LLC
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Advanced Cancer |
| Advanced Solid Tumor |
| Melanoma |
| Metastasis |
| Pleural Mesothelioma |
| Renal Cell Carcinoma |
| MSI-High |
| Mismatch Repair Deficiency |
| Colorectal Cancer |
| Hepatocellular Carcinoma |
| Hepatocellular Cancer |
| Renal Cell Cancer |
| Kidney Cancer |
| Skin Cancer |
| Non Small Cell Lung Cancer |
| NSCLC |
| Anaplastic Lymphoma Kinase Genomic Tumor Aberrations |
| ALK Genomic Tumor Aberrations |